Drug Trial Radar · NCT05835180
A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Last checked: Nov 19, 2026Latest source record: Dec 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
May 1, 2023
Primary completion
Dec 18, 2023
Study completion Dec 18, 2023
Sponsor
- Lead sponsor
- Sagimet Biosciences Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this phase 1 study is to assess the pharmacokinetics, safety and tolerability following multiple oral doses of TVB-2640 in subjects with mild, moderate, or severe hepatic impairment compared to healthy subjects with normal hepatic function.
Conditions
- Non-alcoholic Steatohepatitis
- Hepatic Impairment
- Cirrhosis
Interventions
TVB-2640 - 50 mgDrug
TVB-2640 -50 mg administered orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total TVB-2640 plasma concentration-time (AUC) at steady stateTime frame: Day 4
- Unbound TVB-2640 plasma concentration-time (AUC) at steady stateTime frame: Day 4
- Maximum plasma concentration (Cmax) for total TVB-2640 at steady stateTime frame: Day 4
- Maximum plasma concentration (Cmax) for unbound TVB-2640 at steady stateTime frame: Day 4
- incidence and severity of AEsTime frame: Screening to Day 7
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Thomas C. Marbury
Orlando, Florida
Eric J. Lawitz, MD
San Antonio, Texas
Geza Lakner
Kistarcsa, Hungary
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.